ReviewJournal of clinical medicine2017
Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP).
Review in Journal of clinical medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06093529 (Marker Expression in Pediatric Patients With Immune Thrombocytopenic Purpura Receiving Second Line Therapy), which is not on this map. Cited by 124 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Marker Expression in Pediatric Patients With Immune Thrombocytopenic Purpura Receiving Second Line Therapy
Who cites it
124 citing papers in PubMed, 4 syntheses or guidelines pooled it, 527 citations in OpenAlex.
- Evaluation ofFrontiers in medicine · 2026Pooled it
- Pooled it
- Efficacy and safety of mycophenolate mofetil in patients with immune thrombocytopenic purpura: a systematic review and meta-analysis.Clinical rheumatology · 2024Pooled it
- The Efficacy of High-Dose Dexamethasone vs. Other Treatments for Newly Diagnosed Immune Thrombocytopenia: A Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Efficacy and safety of a new 10% intravenous immunoglobulin (IVIG) in Chinese patients with primary immune thrombocytopenia (ITP): a multicenter, single-arm, phase III trial.Clinical and experimental medicine · 2025Trial
- Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia.Blood advances · 2024Trial
- Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.American journal of hematology · 2019Trial
- Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.American journal of hematology · 2018Trial
- CDK7, CDK9, or CDK11 inhibition reduces neutrophil-driven inflammation and tissue damage in experimental autoimmune models.Cell communication and signaling : CCS · 2026Article
- Association of carotid intima media thickness with cardiovascular disease risk in immune thrombocytopenia.International journal of hematology · 2026Article
- Article
- Post-marketing surveillance of fostamatinib for primary immune thrombocytopenia in Japan: interim analysis.International journal of hematology · 2026Article
- The Evolving Landscape of CAR T-Cell Therapy in Autoimmune Diseases: A State-of-the-Art Review (2025).Clinical reviews in allergy & immunology · 2026Review
- Proteomic Analysis in Search of New Biomarkers of Immune Thrombocytopenia (ITP)-A Review of Current Data.Proteomes · 2026Review
- The PI3K-AKT pathway mediates the imbalance of bone marrow macrophage polarization in patients with immune thrombocytopenia.Journal of translational medicine · 2026Article
- Life-threatening intraparenchymal hematoma due to immune thrombocytopenic purpura: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- A Clinician Perspective for a Personalized Approach to Management of Chronic Immune Thrombocytopenia with Targeted Therapies Alone or in Combination.Journal of clinical medicine · 2026Review
- [Bleeding characteristics in pregnant patients with immune thrombocytopenia and severe thrombocytopenia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Review
- A Detailed Protocol to Induce and Treat Passive Immune Thrombocytopenia in Mice.Methods in molecular biology (Clifton, N.J.) · 2026Article
64 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune thrombocytopenia (ITP) is a complex autoimmune disease characterized by low platelet counts. The pathogenesis of ITP remains unclear although both antibody-mediated and/or T cell-mediated platelet destruction are key processes. In addition, impairment of T cells, cytokine imbalances, and the contribution of the bone marrow niche have now been recognized to be important. Treatment strategies are aimed at the restoration of platelet counts compatible with adequate hemostasis rather than achieving physiological platelet counts. The first line treatments focus on the inhibition of autoantibody production and platelet degradation, whereas second-line treatments include immunosuppressive drugs, such as Rituximab, and splenectomy. Finally, thirdline treatments aim to stimulate platelet production by megakaryocytes. This review discusses the pathophysiology of ITP and how the different treatment modalities affect the pathogenic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.